Ladenburg - Heidelberg Pharma AG (FWB: HPHA), a clinical-stage biotech company developing innovative antibody-drug conjugates (ADCs), announces that it has adjusted the forecast for the current fiscal year published on March 25, 2024.

For the Heidelberg Pharma Group, sales and other income of between EUR 9.0 million and EUR 12.0 million are now expected for the 2024 financial year (previously: EUR 11.0 million to EUR 15.0 million). The reason for the lower sales is that expected sales are likely to be delayed due to developments with the license partners. Operating expenses will continue to be in a corridor between EUR 36.0 million and EUR 40.0 million. Based on these adjustments, an operating result (EBIT) of between EUR -25.5 million and EUR -29.5 million is expected (previously: EUR -23.5 million to EUR -27.5 million).

Heidelberg Pharma expects to require funds of EUR 18.0 million to EUR 22.0 million in 2024 (previously: EUR 28.0 million to EUR 32.0 million). Monthly cash consumption is expected to be between EUR 1.5 million and EUR 1.8 million per month (previously: EUR 2.3 million and EUR 2.7 million). The company's financing is secured until mid-2025 based on current planning and available funds.

Taking into account a further expected payment of USD 75.0 million from HealthCare Royalty, the Company expects, based on current medium-term planning, a financing reach until the end of 2026.

Contact:

Tel: +49 6203 1009-0

Email: info@hdpharma.com

(C) 2024 Electronic News Publishing, source ENP Newswire